List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
31 July 2015 | By Victoria White
Roche submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the FDA, as a companion diagnostic test for AZD9291...
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
14 July 2015 | By Victoria White
The FDA has approved Iressa for the first-line treatment of patients with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations...
9 July 2015 | By Victoria White
Tillotts Pharma has entered into an agreement for the acquisition of the global rights for Entocort from AstraZeneca, excluding the US...
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
2 June 2015 | By Victoria White
Draft guidance issued by NICE on the drug olaparib do not recommend its use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
1 June 2015 | By Victoria White
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of EGFRm advanced non-small cell lung cancer (NSCLC)...
26 May 2015 | By Victoria White
Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab...
24 April 2015 | By Victoria White
Innate Pharma has signed a co-development and commercialisation agreement with AstraZeneca to accelerate and broaden the development of IPH2201...
17 April 2015 | By Victoria White
Latest data from the ongoing AURA study of AZD9291 demonstrated a median progression free survival of 13.5 months in patients with advanced EGFRm NSCLC...
20 March 2015 | By Victoria White
Daiichi Sankyo has announced a co-commercialisation agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US with plans to launch in April 2015..
9 February 2015 | By Pharmaceutical Licensing Group
Pharmaceutical Licensing Group has announced the results of its 8th Annual Awards for excellence in business development which were given at its AGM on 5th February 2015...
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
30 January 2015 | By AstraZeneca and The University of Texas MD Anderson Cancer Center
AstraZeneca and The University of Texas MD Anderson Cancer Center announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes...
